Clinical trial
Monoclonal Antibody Therapy and Docetaxel in Treating Women With Metastatic or…
NCT00028483 · Seagen Inc., Industry · Terminated
Key facts
| NCT number | NCT00028483 |
|---|---|
| Title | Monoclonal Antibody Therapy and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer |
| Official title | A Phase II Study Using SGN-15 (cBR96 - Doxorubicin Immunoconjugate) in Combination With Taxotere for the Treatment of Metastatic or Recurrent Breast Carcinoma |
| Lead sponsor | Seagen Inc., Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | cBR96-doxorubicin immunoconjugate, docetaxel |
| Start date | Oct 1, 2000 |
| Completion | Apr 1, 2003 |
| First posted | Jun 27, 2003 |
| Last update posted | Oct 24, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: